IP Library Patent Application 13347725
Patent Application
App. No. 13/347,725

Composition for Treating Dry Eye and Related Methods of Manufacture and Methods of Use

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/347,725
Abstract

The present invention is directed to a composition for treating dry eye comprising, in one embodiment, carboxymethylcellulose and a polyol. Such compositions have been found to alleviate the symptoms of dry eye and remain in the eye for a long period of time.

Claims (12)

1 . A composition comprising an aqueous solution that comprises carboxy-containing polymer at a concentration from about 0.01 to about 2 percent by weight of the solution, and a single polyol at a concentration from about 0.05 to about 4 percent by weight of the solution, wherein the carboxy-containing polymer has a molecular weight in a range from 90 kDa to 700 kDa, the carboxy-containing polymer comprises carboxy-containing cellulose, and the carboxy-containing polymer has a degree of substitution value in a range from 0.25 to 1, and wherein the polyol contains 2 to 6 carbon atoms.

2 . The composition of claim 1 , wherein the polyol contains 2 to 4 carbon atoms.

3 . The composition of claim 1 , wherein the polyol is glycerin.

4 . The composition of claim 1 , wherein the polyol is propylene glycol.

5 . The composition of claim 1 , wherein the carboxy-containing polymer is carboxymethyl cellulose.

6 . The composition of claim 1 , wherein the carboxy-containing polymer is sodium hyaluronate.

7 . The composition of claim 1 , wherein the polyol is selected from the group consisting of glycerin, ethylene glycol, propylene glycol, sorbitol, mannitol and monosaccharides.

8 . The composition of claim 1 , wherein the carboxy-containing polymer is present at a concentration from about 0.1 to about 1.75 percent by weight of the solution, and the single polyol is present at a concentration from about 0.5 to about 3 percent by weight of the solution.

9 . The composition of claim 1 , wherein the carboxy-containing polymer is present at a concentration from about 0.05 to about 2 percent by weight of the solution, and the single polyol is present at a concentration from about 0.05 to about 3 percent by weight of the solution.

10 . The composition of claim 1 , wherein the carboxy-containing polymer is present at a concentration from about 0.1 to about 1.75 percent by weight of the solution, and the single polyol is present at a concentration from about 0.1 to about 3 percent by weight of the solution.

11 . The composition of claim 1 , wherein the carboxy-containing polymer is present at a concentration from about 0.5 to about 1.75 percent by weight of the solution, and the single polyol is present at a concentration from about 0.5 to about 3 percent by weight of the solution.

12 . The composition of claim 1 , wherein the carboxy-containing polymer is present at a concentration from about 0.05 to about 1.5 percent by weight of the solution, and the single polyol is present at a concentration from about 0.05 to about 2 percent by weight of the solution.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2012
From: XIA, ERNING; SALAMONE, JOSEPH C.; LIU, X. MICHAEL
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 027599/0160 →